Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENDIMETRAZINE TARTRATE vs DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phendimetrazine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, leading to decreased food intake and increased energy expenditure. It is a prodrug that is metabolized to phenmetrazine, which is a potent central nervous system stimulant with amphetamine-like effects.
Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.
Management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction,Off-label: treatment of obesity with comorbid conditions where weight loss is beneficial
Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis,Relief of nasal congestion associated with allergic rhinitis or common cold
Oral: 35 mg twice daily or three times daily, 1 hour before meals; extended-release: 105 mg once daily in the morning.
One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.
Terminal half-life 3-4 hours; clinical context: requires multiple daily dosing
Desloratadine: 27 hours (terminal); pseudoephedrine sulfate: 5-8 hours (terminal, dependent on urine p H).
Primarily metabolized in the liver via N-demethylation to its active metabolite, phenmetrazine. Other metabolites include phendimetrazine N-oxide and norphenmetrazine. CYP450 enzymes are involved, though specific isoforms not well characterized.
Desloratadine is metabolized to 3-hydroxydesloratadine via CYP2C8 and CYP3A4. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Primarily renal (≥70% unchanged) with minor biliary/fecal elimination (<10%)
Desloratadine: 41% urine (metabolites), 47% feces (metabolites); pseudoephedrine sulfate: 70-90% renal (unchanged), 1% biliary.
10-15% bound to albumin
Desloratadine: 83-87% bound (primarily albumin); pseudoephedrine sulfate: minimal binding, ~20% bound.
2-3 L/kg; indicates extensive tissue distribution
Desloratadine: ~16.8 L/kg (high Vd, extensive tissue distribution); pseudoephedrine sulfate: ~2.6-3.5 L/kg (moderate Vd).
Oral: approximately 80-90%
Desloratadine: 76% (oral); pseudoephedrine sulfate: ~100% (extended-release formulation).
Contraindicated in severe renal impairment (GFR < 30 m L/min). No specific dose adjustments for mild-moderate impairment; use with caution.
Contraindicated in GFR < 30 m L/min. For GFR 30-59 m L/min: not recommended due to lack of data. For GFR ≥ 60 m L/min: no adjustment needed.
Not recommended in Child-Pugh class B or C. Use with caution in mild impairment.
No specific Child-Pugh based recommendations. Use with caution in severe hepatic impairment; desloratadine clearance reduced.
Not recommended for children under 12 years; safety and efficacy not established.
Not approved for pediatric patients; safety and efficacy not established in children <12 years. For ≥12 years: same as adult.
Start at lower end of dosing range; monitor for increased sensitivity and cardiovascular effects.
Use with caution due to increased sensitivity, risk of CNS effects, and potential renal impairment. Consider starting at lower doses; avoid in patients with severe renal impairment.
Phendimetrazine is not approved for use in patients with a history of drug abuse or dependence. It has a high potential for abuse and may lead to dependence. Use caution in patients with cardiovascular disease or hypertension.
None.
Increased risk of pulmonary hypertension and valvular heart disease; monitor for dyspnea, chest pain, or edema. Tolerance may develop; discontinue if tolerance occurs. May impair ability to perform hazardous tasks. Use with caution in patients with hypertension, diabetes, or glaucoma. Do not use with MAOIs or within 14 days of discontinuation.
Severe hypertension and/or tachycardia,Cardiovascular disease including ischemic heart disease and arrhythmias,Increased intraocular pressure,Diabetes mellitus,Thyroid dysfunction,Prostatic hypertrophy/urinary retention,Renal impairment,Seizure disorders,Use in elderly patients
Hypersensitivity to phendimetrazine or any component of the formulation, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse, during or within 14 days of MAOI therapy
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension,Coronary artery disease,Use of MAO inhibitors within 14 days,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
Avoid alcohol and excessive caffeine (coffee, tea, energy drinks) as they may increase CNS stimulation and risk of side effects. Take with or without food; high-fat meals may delay absorption of extended-release formulations. Maintain a calorie-reduced diet as part of a comprehensive weight loss plan.
Avoid alcohol as it may increase sedative effects. Limit or avoid caffeine-containing foods/drinks (coffee, tea, soda, chocolate) to reduce risk of nervousness, insomnia, and tachycardia. No specific food interactions with desloratadine; pseudoephedrine is not significantly affected by food.
First trimester: Limited data; potential for increased risk of oral clefts. Second/third trimester: Anorexiant effects may cause fetal growth restriction; avoid use due to maternal hypertension risk.
Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester; possible uterine vasoconstriction in second/third trimester. Overall, avoid in first trimester; use only if benefit outweighs risk in second/third trimester.
Excreted in breast milk; M/P ratio unknown. Contraindicated in breastfeeding due to potential CNS stimulation and cardiovascular effects in infant.
Desloratadine: low excretion into breast milk; M/P ratio not established. Pseudoephedrine: small amounts in milk; peak milk concentration at 2-4 hours; M/P ratio 1.7-3.5. May cause irritability or sleep disturbance in infants; reduce breast milk production. Not recommended during breastfeeding.
Contraindicated in pregnancy; no dose adjustments recommended. Avoid use due to risks of hypertension and potential teratogenicity.
No pharmacokinetic data in pregnancy; standard dosing not recommended due to risk profile. Use only if clearly needed and under medical supervision.
Phendimetrazine tartrate is a schedule III controlled substance with high abuse potential. It is approved only for short-term (up to 12 weeks) monotherapy for exogenous obesity. Contraindicated in patients with glaucoma, hyperthyroidism, agitated states, history of drug abuse, or cardiovascular disease. Taper dose to avoid withdrawal. Monitor blood pressure and heart rate; may cause pulmonary hypertension. Avoid use with MAOIs (risk of hypertensive crisis) and within 14 days of discontinuation.
Desloratadine is a long-acting antihistamine; pseudoephedrine sulfate is a nasal decongestant. The 24-hour formulation provides extended relief. Use with caution in patients with hypertension, hyperthyroidism, or benign prostatic hyperplasia. Avoid in narrow-angle glaucoma. Monitor for insomnia and nervous system stimulation. May cause dry mouth and urinary retention.
Take exactly as prescribed; do not increase dose or duration.,Take last dose of the day 4-6 hours before bedtime to prevent insomnia.,Do not crush or chew extended-release tablets; swallow whole.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Report chest pain, shortness of breath, fainting, or leg swelling immediately.,Do not stop abruptly; follow your doctor's tapering plan.,Store securely; keep out of reach of others as this medication can be habit-forming.,Do not take with alcohol or other CNS stimulants.,Use with caution if you have high blood pressure, diabetes, or a history of depression.
Take one tablet daily with a full glass of water; do not crush or chew.,Avoid taking with other sympathomimetic amines (e.g., pseudoephedrine, phenylephrine) to prevent excessive cardiovascular stimulation.,May cause drowsiness; avoid driving or operating heavy machinery until you know how the medication affects you.,Limit caffeine intake to reduce additive stimulant effects.,Do not use if you have severe hypertension, coronary artery disease, or are taking MAOIs currently or within past 14 days.
"Ketazolam, a benzodiazepine, can cause central nervous system (CNS) depression. Desloratadine, a nonsedating antihistamine, has a low potential for CNS depression at therapeutic doses. However, when combined with benzodiazepines, the risk of additive CNS depressant effects increases, potentially leading to excessive sedation, dizziness, and impaired psychomotor function. This interaction is particularly relevant in patients with hepatic impairment or those taking higher doses of either drug."
"Paroxetine, a potent inhibitor of CYP2D6, can increase plasma concentrations of desloratadine, which is partially metabolized by CYP2D6. This elevation in desloratadine levels may potentiate its antihistaminic effects and, more rarely, its cardiac adverse effects such as QT prolongation. Although desloratadine has a low propensity for QT prolongation, the additive serotonergic effects are unlikely, but the interaction is primarily pharmacokinetic, leading to increased exposure and potential dose-related adverse events."
"The coadministration of methadyl acetate and desloratadine may lead to additive QT interval prolongation due to their respective cardiac repolarization effects. Methadyl acetate, as a µ-opioid receptor agonist and known QT-prolonging agent, increases the risk of torsade de pointes and other ventricular arrhythmias. Desloratadine, an antihistamine, possesses weak blocking activity of the hERG potassium channel, which can further potentiate the QT prolongation when combined, resulting in increased risk of life-threatening cardiac arrhythmias, especially in patients with pre-existing risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENDIMETRAZINE TARTRATE vs DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, answered by our medical review team.
PHENDIMETRAZINE TARTRATE is a Anorectic (Sympathomimetic) that works by Phendimetrazine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, leading to decreased food intake and increased energy expenditure. It is a prodrug that is metabolized to phenmetrazine, which is a potent central nervous system stimulant with amphetamine-like effects.. DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is a Sympathomimetic that works by Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Pseudoephedrine sulfate is an alpha-adrenergic receptor agonist causing vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENDIMETRAZINE TARTRATE and DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENDIMETRAZINE TARTRATE is: Oral: 35 mg twice daily or three times daily, 1 hour before meals; extended-release: 105 mg once daily in the morning.. The standard adult dose of DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is: One tablet (desloratadine 5 mg/pseudoephedrine sulfate 240 mg) orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENDIMETRAZINE TARTRATE and DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENDIMETRAZINE TARTRATE is classified as Category C. First trimester: Limited data; potential for increased risk of oral clefts. Second/third trimester: Anorexiant effects may cause fetal growth restriction; avoid use due to maternal. DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is classified as Category A/B. Desloratadine: no human data, animal studies show no evidence of harm; risk cannot be excluded. Pseudoephedrine: associated with increased risk of gastroschisis in first trimester;. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.